Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.

Autor:	Piscopo NJ; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.; Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA., Mueller KP; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.; Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA., Das A; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.; Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA., Hematti P; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Murphy WL; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.; Department of Orthopedics and Rehabilitation, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Palecek SP; Department of Chemical and Biological Engineering, University of Wisconsin, Madison, WI, USA., Capitini CM; University of Wisconsin Carbone Cancer Center, Madison, WI, USA.; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Saha K; Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.; Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA.; University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Jazyk:	angličtina
Zdroj:	Biotechnology journal [Biotechnol J] 2018 Feb; Vol. 13 (2). Date of Electronic Publication: 2017 Sep 18.
DOI:	10.1002/biot.201700095
Abstrakt:	The next generation of therapeutic products to be approved for the clinic is anticipated to be cell therapies, termed "living drugs" for their capacity to dynamically and temporally respond to changes during their production ex vivo and after their administration in vivo. Genetically engineered chimeric antigen receptor (CAR) T cells have rapidly developed into powerful tools to harness the power of immune system manipulation against cancer. Regulatory agencies are beginning to approve CAR T cell therapies due to their striking efficacy in treating some hematological malignancies. However, the engineering and manufacturing of such cells remains a challenge for widespread adoption of this technology. Bioengineering approaches including biomaterials, synthetic biology, metabolic engineering, process control and automation, and in vitro disease modeling could offer promising methods to overcome some of these challenges. Here, we describe the manufacturing process of CAR T cells, highlighting potential roles for bioengineers to partner with biologists and clinicians to advance the manufacture of these complex cellular products under rigorous regulatory and quality control. (© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text